NCT00874614 2020-02-20A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/ParagangliomaMolecular Insight Pharmaceuticals, Inc.Phase 2 Unknown74 enrolled 10 charts 1 FDA
NCT02961491 2019-01-30Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/ParagangliomaMolecular Insight Pharmaceuticals, Inc.Approved for marketing
NCT00458952 2016-07-13Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/ParagangliomaMolecular Insight Pharmaceuticals, Inc.Phase 1/2 Completed24 enrolled 8 charts